sm03
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Aug 14, 2012 (NCT04704492)
Timeline
Indications
Studied for
Mechanism of action
- CD22INHIBITOR
CD22 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04312815 | Phase 3 | Dec 28, 2017 | SinoMab Pty Ltd |
| NCT04192617 | Phase 2 | Dec 31, 2014 | SinoMab Pty Ltd |
| NCT04704492 | Phase 1 | Aug 14, 2012 | Peking University, SinoMab Pty Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SinoMab Pty Ltd | For profit | 3 | 3 | 3 | 2012 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2012 |
2 organizations
Page 1 / 1